Position in OCGN
as of Jun 30, 2026
· filed Jul 29, 2026
Position Value
$40,545
-$7,420 QoQ
Shares Held
26,500
0.0% QoQ
Ownership
0.008%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#8
of 35 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in OCGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Verdence Capital Advisors LLC holds $3,978,199 across 8 Biotechnology names. OCGN ranks #7 (1.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TECH |
BIO-TECHNE Corp
|
14,342 | $1,013,262 | |
| 2 | HALO |
Halozyme Therapeutics, Inc.
|
12,488 | $977,435 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,901 | $944,283 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
954 | $594,857 | |
| 5 | VCEL |
Vericel Corp
|
6,754 | $300,485 | |
| 6 | ATAI |
AtaiBeckley Inc.
|
19,251 | $101,452 | |
| 7 | OCGN |
Ocugen, Inc.
This page
|
26,500 | $40,545 | |
| 8 | GTBP |
GT Biopharma, Inc.
|
12,000 | $5,880 |
All Filings in OCGN
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $40,545 | 26,500 | Shares | Sole | 2026-07-29 | |
| 2026-03-31 | $47,965 | 26,500 | Shares | Sole | 2026-04-30 | |
| 2025-12-31 | $44,550 | 33,000 | Shares | Sole | 2026-01-29 | |
| 2025-09-30 | $48,900 | 30,000 | Shares | Sole | 2025-10-29 | |
| No filing history on record for this holder in this stock. | ||||||